During the past decade, Hiroshima Prefectural Hospital conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 5 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 5 clinical trials were completed. i.e. 41.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hiroshima Prefectural Hospital" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Chugai Pharmaceutical" with 2 trials sponsored, "Daiichi Sankyo Co., Ltd." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Biotronik SE & Co. KG" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima Prefectural Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima Prefectural Hospital" are "Colorectal Cancer" (2 trials), "Heart Failure" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Atypical Hemolytic Uremic Syndrome" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Hiroshima Prefectural Hospital" in a lesser frequency.

Most popular intervention types in "Hiroshima Prefectural Hospital" are "Drug" (14 trials), "Device" (3 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "ASA 100 mg" (1 trials), "Cardiac Resynchronization Therapy (CRT)" (1 trials), "Crovalimab" (1 trials) and "DS-8201a" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima Prefectural Hospital" are 19 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hiroshima Prefectural Hospital". undefined are not yet recruiting, 4 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Hiroshima Prefectural Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima Prefectural Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".